Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Adenocarcinoma
Interventions:   Biological: CRS-207;   Biological: Pembrolizumab
Sponsors:   Aduro Biotech, Inc.;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified April 2017

http://ift.tt/2pMfAEd